Related Experiment Videos
[The new indications for permanent cardiac pacing]
1Hospital Garcia de Orta, Almada.
Summary
Dual-chamber pacing offers new therapeutic options for hypertrophic cardiomyopathy and heart failure. It effectively reduces gradients in obstructive hypertrophic cardiomyopathy and may benefit select heart failure patients.
Area of Science:
- Cardiology
- Medical Devices
- Electrophysiology
Context:
- Pacing is increasingly used beyond traditional indications.
- Conflicting data exists regarding its efficacy in new applications.
- Focus on hypertrophic cardiomyopathy, heart failure, and atrial fibrillation prevention.
Purpose:
- Review new indications for pacing therapy.
- Discuss utilization criteria, technical aspects, and trial results.
- Evaluate dual-chamber pacing in hypertrophic cardiomyopathy and heart failure.
Summary:
- Dual-chamber pacing significantly reduces left ventricular outflow tract gradients and improves symptoms in obstructive hypertrophic cardiomyopathy.
- Specific criteria for pacemaker therapy in hypertrophic cardiomyopathy include persistent symptoms and significant gradients.
- In severe heart failure (NYHA class III-IV, EF <35%), benefits are limited to patients with specific echocardiographic and ECG findings (long PR, presystolic mitral regurgitation, abbreviated diastolic filling).
- Preliminary data suggests pacing may reduce atrial fibrillation episodes in certain patient subsets.
- Noninvasive detection of cardiac allograft rejection via pacing parameters is experimental.
Impact:
- Provides evidence-based criteria for utilizing pacing in challenging cardiac conditions.
- Highlights patient selection for optimizing outcomes in hypertrophic cardiomyopathy and heart failure.
- Suggests potential for pacing in atrial fibrillation management and transplant monitoring.